Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV) is a healthcare company (biotechnology) based in the United Kingdom. The share price is $38.07, down 1.40% on the day, which values the company at $27.58B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.
Key facts
- Share price
- $38.07−1.40% today
- Market value
- $27.58B
- Funk Score
- 22/100
- Against its own history
- Well above its usual priceusual price $7.76
- 200-week average
- $16.18135% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Roivant Sciences Ltd. in more detail
ROIV trades at -26.6× next year's expected earnings, 671.4× sales. Measured against its own history, the price is 391% above what its usual multiples would imply ($7.76) — well above its usual price. It sits 135% above its 200-week average of $16.18.
Over the last five fiscal years Roivant Sciences Ltd. has compounded revenue -19.1% a year. Its Funk Score is 22 out of 100 (financial strength 7.0, profitability 0.3, growth 1.3, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Heavy stock-based pay.
6 of the superinvestors tracked here hold ROIV, including Andrew Spokes (4.1% of the portfolio), David Einhorn (1.9% of the portfolio), Lee Ainslie (0.9% of the portfolio).
Superinvestors holding ROIV
6 of the investors tracked here report a position in their latest 13F filing.
- Andrew Spokes Farallon Capital Management4.14% of portfolio · $795.2M · added · Q3 2026
- David Einhorn Greenlight Capital1.95% of portfolio · $76.2M · Q2 2026
- Lee Ainslie Maverick Capital0.90% of portfolio · $100.1M · added · Q2 2026
- Julian and Felix Baker Baker Bros. Advisors0.84% of portfolio · $166.9M · trimmed · Q2 2026
- Andreas Halvorsen Viking Global Investors0.63% of portfolio · $221.9M · trimmed · Q2 2026
- Steve Cohen Point72 Asset Management0.24% of portfolio · $158.3M · added · Q2 2026
Health Care companies of similar size
- CenteneCNC
- GenmabGMAB
- IlluminaILMN
- ResMedRMD
- ZoetisZTS
- Labcorp HoldingsLH
- DexComDXCM
- Koninklijke PhilipsPHG
- West Pharmaceutical ServicesWST
- Quest DiagnosticsDGX
- STERISSTE
- InsmedINSM
Side by side:ROIV vs WST (Roivant Sciences Ltd. vs West Pharmaceutical Services)ROIV vs DGX (Roivant Sciences Ltd. vs Quest Diagnostics)ROIV vs PHG (Roivant Sciences Ltd. vs Koninklijke Philips)ROIV vs DXCM (Roivant Sciences Ltd. vs DexCom)ROIV vs LH (Roivant Sciences Ltd. vs Labcorp Holdings)
All health care companies by market valueLargest companies in the United KingdomAll stocks A–Z
Roivant Sciences Ltd. (ROIV): questions and answers
What is Roivant Sciences Ltd.'s market cap?
Roivant Sciences Ltd. is valued at $27.58B at a share price of $38.07.
Is ROIV overvalued or undervalued?
Against its own history, ROIV is well above its usual price: the price is 391% above the $7.76 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is ROIV above its 200-week moving average?
Yes. ROIV is 135.3% above its 200-week average of $16.18. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Roivant Sciences Ltd. growing?
Over the last five fiscal years Roivant Sciences Ltd.'s revenue grew -19.1% a year.
Does ROIV pay a dividend?
Roivant Sciences Ltd. does not currently pay a regular dividend.
Which famous investors own ROIV?
In their latest quarterly filings, Andrew Spokes (4.1% of the portfolio), David Einhorn (1.9% of the portfolio), Lee Ainslie (0.9% of the portfolio), Julian and Felix Baker (0.8% of the portfolio), Andreas Halvorsen (0.6% of the portfolio), Steve Cohen (0.2% of the portfolio) hold ROIV. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Roivant Sciences Ltd. (ROIV) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ROIV
Underlying data: Yahoo Finance; company filings with the SEC.